Korean Pharma Finds Own Way To Collaborative And Open Innovation
Taking into consideration global and domestic trends, South Korean pharmas are increasingly finding their own strategies to seek open innovation and collaborations to develop novel new drugs. Two leading firms from the country shared their know-how and showcased successful open innovation cases during a recent gathering organized by a national industry association.
You may also be interested in...
Yuhan inks long-awaited, major global license agreement for its novel third-generation EGFR TKI with Janssen, in a $1.2bn deal poised to boost the South Korean firm's ongoing R&D efforts in key therapeutic areas, while Janssen will further beef up its oncology portfolio. But competition with entrenched rival Tagrisso awaits.
South Korean pharma firm licenses out to US venture Spine Biopharma novel peptide drug for degenerative disc disease YH14618, despite a Phase II failure and trial halt in 2016.
Several South Korean companies are set to present updates on their growing lung cancer pipelines at a major meeting in Chicago this month, underlining the high unmet needs and strong R&D interest in this area by firms in the country.